It is associated with poor prognosis [96,97,98], metastasis [99], drug resistance [100], and tumour recurrence [101,102] in hepatocellular carcinoma; loss of p53 heterozygosity in breast cancer cells [103]; and poor prognosis [104] and drug resistance in lung cancer [105], ovarian cancer [106], and myeloma [107,108,109]. Here, TP53 is linked to neoplasm.